Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Am J Surg Pathol. 2021 Jul 1;45(7):951–961. doi: 10.1097/PAS.0000000000001685

Table 1:

Patient Characteristics

Double Positive Discordant Double Negative Total Significance
(n=377) (n=23) (n=67) (n=467) (P)
Demographics/Baseline Characteristics
Age, Mean years (SD) 57 (9) 57 (13) 58 (11) 57.1 (9.6) 0.69
Sex, Male, N (%) 342 (91) 21 (91) 48 (72) 411 (88.0) < 0.001
Race, Caucasian, N (%) 360 (95) 21 (91) 45 (67) 426 (91.2) < 0.001
Smoking Status, N (%) Never Smoker 154 (41) 7 (30) 6 (9) 167 (35.8) < 0.001
Former or Current Smoker 221 (59) 16 (70) 61 (91) 298 (63.8)
p16-Status, N (%) Positive 384 (82.2)
Negative 83 (17.8)
HPV mRNA, N (%) Positive 393 (84.2)
Negative 74 (15.9)
Initial Classification, N (%) p16-negative/HPV-negative 67 (14.4)
p16-negative/HPV-positive 16 (3.4)
p16-positive/HPV-negative 7 (1.5)
p16-positive/HPV-positive 377 (80.7)
Clinical T Stage, N (%) T0 - T2 286 (76) 15 (65) 31 (46) 332 (71.1) < 0.001
T3 - T4 91 (24) 8 (35) 34 (51) 133 (28.5)
Morphology, N (%) Nonkeratinizing 253 (67) 7 (30) 4 (6) 264 (56.5) < 0.001
Nonkeratinizing with Maturation 93 (25) 11 (48) 10 (15) 114 (24.4)
Keratinizing 10 (3) 4 (17) 52 (78) 66 (14.1)
Other 21 (6) 1 (4) 1 (1) 23 (4.9)
Treatment, N (%) Definitive Radiation 122 (32) 10 (43) 27 (40) 159 (34.1) < 0.001
Postoperative Radiation 216 (57) 11 (48) 23 (34) 250 (53.5)
Surgery Alone 35 (9) 0 (0) 9 (13) 44 (9.4)
Other 4 (1) 2 (9) 8 (12) 14 (3.0)
Chemotherapy, N (%) 252 (67) 18 (78) 35 (52) 305 (65.3) 0.04
p16/HPV Reclassification, N (%) Negative 0 (0) 3 (13) 67 (100) 70 (15.0) < 0.001
Positive 376 (100) 20 (87) 0 (0) 396 (84.8)